Premium
Synthesis of β‐amino acid derivatives and their inhibitory profiles against some metabolic enzymes
Author(s) -
Atmaca Ufuk,
Daryadel Shahla,
Taslimi Parham,
Çelik Murat,
Gülçin İlhami
Publication year - 2019
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.201900200
Subject(s) - chemistry , butyrylcholinesterase , enzyme , acetylcholinesterase , isozyme , carbonic anhydrase , biochemistry , cholinesterase , stereochemistry , carbonic anhydrase i , amino acid , aché , pharmacology , medicine
Sulfamate and its derivatives have a range of biological activities. One‐pot cyclocondensation of alkenes ( 1a–i ) with chlorosulfonyl isocyanate generates β‐lactams. β‐Amino acid derivatives ( 2a–i ) from β‐lactams were synthesized. Then, these highly reactive compounds were opened with MeOH to produce the corresponding sulfamate derivatives in good yields. The inhibitory effects of the novel sulfamate derivatives were tested on human carbonic anhydrase I and II isoenzymes (hCA I and hCA II), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and α‐glycosidase (α‐Gly). Novel sulfamate derivatives showed K i values in the range of 23.81–42.97 nM against hCA I, 8.95–52.23 nM against hCA II, 8.10–45.51 nM against AChE, 23.16–81.84 nM against BChE, and 14.02–48.68 nM against α‐Gly. As a result, the novel sulfamate derivatives had potent inhibitory effects against both isoenzymes. Overall, due to the inhibitory effects of the novel sulfamate derivatives on the tested metabolic enzymes, they are promising drug candidates for the treatment of diseases like glaucoma, epilepsy, leukemia, Alzheimer's disease, and type 2 diabetes mellitus, which are associated with high enzymatic activity of the indicated metabolic enzymes.